Compare OESX & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OESX | GANX |
|---|---|---|
| Founded | 1996 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.7M | 52.2M |
| IPO Year | 2007 | 2021 |
| Metric | OESX | GANX |
|---|---|---|
| Price | $12.78 | $1.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $36.00 | $6.60 |
| AVG Volume (30 Days) | 37.2K | ★ 523.5K |
| Earning Date | 11-05-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.46 |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $86,306,000.00 | $55,180.00 |
| Revenue This Year | $17.95 | N/A |
| Revenue Next Year | $10.38 | N/A |
| P/E Ratio | $48.43 | ★ N/A |
| Revenue Growth | ★ 8.26 | N/A |
| 52 Week Low | $8.58 | $0.94 |
| 52 Week High | $31.65 | $4.34 |
| Indicator | OESX | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 27.08 | 32.93 |
| Support Level | $8.98 | $0.94 |
| Resistance Level | $21.13 | $2.01 |
| Average True Range (ATR) | 1.60 | 0.10 |
| MACD | -0.46 | 0.01 |
| Stochastic Oscillator | 14.19 | 22.54 |
Orion Energy Systems Inc provide light emitting diode (LED) lighting systems, wireless Internet of Things (IoT) enabled control solutions, commercial and industrial electric vehicle charging infrastructure solutions and lighting and electrical maintenance services. It help its customers achieve their sustainability, energy savings and carbon footprint reduction goals through technology and exceptional service. It sell its products and services into many vertical markets within the broader commercial and industrial market segment. Primary verticals include box retail, manufacturing, warehousing/logistics, federal and municipal government, healthcare and schools. It has three segments Lighting, Maintenance, and EV segment. It generates majority of revenue from Lighting segment.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.